Skip to main content
Psychedex
Article

Pregabalin Facts

Depressant; Anxiolytic; Gabapentinoid; Alpha-2-delta voltage-gated calcium channel blocker

Description

Pregabalin — sold as Lyrica — is a synthetic depressant and anxiolytic of the gabapentinoid class. It works by reducing calcium flow into overactive nerve endings, quieting the excitatory signals that drive pain and anxiety.[1][2]

Subjective effects include anxiety suppression, sedation, pain reduction, euphoria, disinhibition, and a warm bodily calm. At therapeutic doses the experience is defined by what it removes — anxiety recedes and pain softens; at recreational doses, buoyant euphoria and social loosening take over.[3]

Physical dependence can develop within two months of regular use, even at prescribed doses;[4] alone, pregabalin is rarely fatal. The danger lies in combination: adding opioids or other depressants amplifies respiratory depression, and nearly all documented deaths follow this pattern.[5][6]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 25 mgLight25 – 75 mgCommon75 – 300 mgStrong300 – 600 mgHeavy600+ mg

Starts in 15 – 30 minLasts 5 – 8 hoursAfter-effects 2 – 6 hours

Body and dependence

Acute toxicity
Low
Chronic toxicity
Moderate
Physical dependence
Moderate
Psychological dependence
Moderate
Withdrawal
Moderate · medical supervision
Compulsive redosing
Moderate

Tolerance

Builds
Moderate
Fully resets after
Not recorded
Carries over to
gabapentin

Effectslikely at a common dose

Perception
none likely · 9 possible, including Visual acuity suppression, Double vision, Spatial disorientation
Body
Pain suppression; +10 possible, including Dizziness, Motor control impairment
Thinking
none likely · 11 possible, including Cognitive impairment, Information processing suppression, Analysis suppression
Feeling
none likely · 3 possible
Self
none likely · 5 possible, including Craving

Who shouldn't take it

Absolute
Concurrent opioid use; Severe renal impairment; Pregnancy
Relative
Heart failure; Concurrent benzodiazepine or Z-drug use; Substance use disorder history; Concurrent alcohol use

Combinations60 recorded

Dangerous (11)
Benzodiazepines, Barbiturates; Buprenorphine, Kratom; Clonidine, Guanfacine; Opioids; SNRIs; Alpha-2 adrenergic receptor antagonist; Benzodiazepines; GHB, Baclofen; GHB, GBL; Ketamine, DXM, PCP; Synthetic cannabinoids
Caution (26)
See full page: psychedex.org/substances/pregabalin
Not graded (23)
Not listed never means safe.

Seek help immediately if

  • Extreme drowsiness — can't stay awake or be roused
  • Confusion, slurred speech, severe loss of coordination
  • Slow, shallow, or irregular breathing
  • Unconsciousness / unresponsive; limp, floppy body
  • Blue lips or fingertips
  • Vomiting while sedated (choking / aspiration risk)
  • Cold, clammy skin; weak pulse

What to do

  1. Try to wake them — shout, firm sternal rub
  2. If unresponsive or breathing is impaired, call emergency services
  3. Place them in the recovery position — critical, they can choke on vomit
  4. Monitor breathing continuously; be ready to give rescue breaths / CPR
  5. Never leave them alone to "sleep it off"
  6. Do not give other drugs, stimulants, or more depressants

Most depressant overdoses resolve with airway protection, breathing support, and monitoring. The danger is respiratory depression and choking on vomit — sharply worse when combined with opioids or alcohol. GHB/GBL overdoses often involve sudden deep unconsciousness and may self-resolve, but airway protection is essential.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Lynch JJ, Honore P, Anderson DJ, et al. (2006) Alpha2delta subunit voltage-gated calcium channel ligands: Ki values and anti-allodynic effects comparison. — Pain PMID:16781071
  2. [2]
    ^Bauer CS, Nieto-Rostro M, Rahman W, et al. (2009) The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. — Journal of Neuroscience doi:10.1523/jneurosci.0356-09.2009
  3. [3]
    ^Schifano F (2014) Misuse and abuse of pregabalin and gabapentin: cause for concern? — CNS Drugs doi:10.1007/s40263-014-0164-4
  4. [4]
    ^Ishikawa H, Takeshima M, Ishikawa H, Ayabe N, Ohta H, Mishima K (2021) Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review. — Neuropsychopharmacology Reports doi:10.1002/npr2.12195
  5. [5]
    ^Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M (2021) Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance. — Frontiers in Psychiatry doi:10.3389/fpsyt.2021.639780
  6. [6]
    ^Shintani-Ishida K, Kawamoto M, Kondo H, Onoe T, Ikegaya H (2024) Fatal pregabalin poisoning in Japan: A case report. — Legal Medicine (Tokyo) doi:10.1016/j.legalmed.2024.102522
Print version
Report an issue